Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to improve prostate cancer detection for trans community

NCT ID NCT06987045

Knowledge-focused Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is figuring out what normal PSA levels are for trans women and non-binary people who have a prostate. Researchers will measure PSA in 500 volunteers aged 40 and older who are on hormones or have had lower surgery. The goal is to help doctors better detect prostate cancer in this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could establish normal PSA ranges for trans women and non-binary people, helping doctors detect prostate cancer earlier in this group.
What could go wrong
This is an observational study, not a treatment trial. It may not change clinical practice immediately, and results depend on the specific group studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Trans and non-binary people with a prostate (TNBPP) who are taking Gender-Affirming Hormone Therapy (GAHT) and/or have had bilateral orchidectomy.

Ages

40 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Aged \>40 * Transgender or non-binary (identify with a gender other than the one assigned at birth) * With a prostate * Fulfills at least one of the following 3 criteria with regards to gender-affirming medical care: * Taking oestradiol for at least the last 3 months * Taking anti-androgens for at least the last 3 months * Ever had bilateral orchidectomy * Eligible for National Health Service (NHS) treatment Exclusion Criteria: * • History of prostate cancer (Prostate cancer) at any time * History of prostate surgery at any time * History of prostate radiotherapy at any time * History of benign prostatic hypertrophy (enlarged prostate) at any time * Vaginoplasty within 12 months * Orchidectomy or vulvoplasty within three months * Sexually Transmitted Infection (STI) within 6 weeks of blood sample * Active urinary infection or within 6 weeks of blood sample * Prostatitis within 6 weeks of blood sample * Urological intervention (e.g. prostate biopsy) within 6 weeks of blood sample * Unwilling to give consent * Lacking capacity to give consent * In the secure estate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate ca are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate ca

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ambrose King Centre, Barts Health NHS Trust

    RECRUITING

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.